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Immune cells and cytokines can either promote or repress
angiogenesis in physiological and pathological processes.
We previously showed that low level IL-12 gene therapy
blocked Kaposi's sarcoma (KS) xenograft growth in vivo
by angiogenesis inhibition. Recruitment and activation of
neutrophils and monocytes, critical regulators of immune
response and IL-12 producers, are repressed by angiosta-
tin, an anti-angiogenic molecule that also inhibits KS
xenograft growth, and whose mechanism remains poorly
understood. We reasoned that angiostatin could induce
angiostatic cytokines by immune cells. Angiostatin
retained its capacity to repress angiogenesis in IFNγ gene
targeted animals. Function blocking antibodies to IL-12
strongly reverted angiostatin inhibition of angiogenesis.
Angiostatin lost its anti-angiogenic potential in animals
gene targeted for the IL-12 receptor IL12RB2 as well as in
animals with the IL-12 p40 subunit deleted. The interfer-
ence of angiostatin action was specific as fenretinide
retained angiostatic activity. Endothelial cells lack an IL-
12 receptor and do not respond to IL-12 stimulation in
vitro, indicating that a secondary immune cell mediated
signal is required in the angiostatic cascade induced by IL-
12. Taken together, these data show that angiostatin
induces IL-12 production by either/or neutrophils, mac-
rophages, dendritic cells, resulting in IL-12 production
that is a key component in angiostatin action. It is clear
that the immune system is tightly intertwined with the
vascular system and that angiogenesis inhibitors may
principally target immune components rather than vascu-
lar cells.
from 2006 International Meeting of The Institute of Human Virology
Baltimore, USA. 17–21 November, 2006
Published: 21 December 2006
Retrovirology 2006, 3(Suppl 1):S80 doi:10.1186/1742-4690-3-S1-S80
<supplement> <title> <p>2006 International Meeting of The Institute of Human Virology</p> </title> <note>Meeting abstracts. A single PDF containing all abstracts in this Supplement is available <a href=" http://www.biomedcentral.com/content/files/pdf/1742-4690-3-S1-full.pdf ">here</a></note> <url>http://www.biomedcentral.com/content/pdf/1742-4690-3-S1-info.pdf</url></supplement>
© 2006 Noonan et al; licensee BioMed Central Ltd. 